Edwards Lifesciences receives FDA clearance for first expandable pediatric pulmonary valve
Edwards Lifesciences announced that the U.S. Food and Drug Administration approved its AUTUS Size‑Adjustable Valve, a surgical pulmonary valve that can be expanded as a child grows. The approval is based on a pivotal study of 62 pediatric patients that showed 100 % freedom from device‑related complications at 30 days and favorable outcomes through one year. The valve starts at roughly 13 mm and can be enlarged to 22 mm using a minimally invasive transcatheter procedure, using synthetic polymeric leaflets.
Why it matters
The clearance gives Edwards a new product line in the pediatric congenital heart disease market, potentially reducing repeat open‑heart surgeries and expanding its addressable patient base. The company’s share price moved higher after the announcement, reflecting investor optimism about the growth opportunity.
Key facts
- 1The U.S. FDA approved the AUTUS Size‑Adjustable Valve for pediatric pulmonary valve replacement. rttnews.com
- 2The device is the first FDA‑approved surgical pulmonary valve designed for pediatric anatomy that can be expanded as a child grows. rttnews.com
- 3The pivotal study enrolled 62 pediatric patients. benzinga.com
- 4All 62 patients were free from device‑related complications through 30 days. benzinga.com
- 5No valve reinterventions were reported through six months, and one‑year follow‑up showed favorable outcomes with no reinterventions. rttnews.com
- 6The valve starts at an initial implant size of roughly 13 mm and can be expanded up to 22 mm. benzinga.com
Open questions
- Share price reported as $85.19 (material 1), $86.08 (material 2) and $85.37 (material 3).
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.